Yo GeoDan Check email on Seeking alpha,
What are your thoughts on NervGEN?
What are your thoughts on NervGEN?
Recent NGEN News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/22/2026 09:24:31 PM
- Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] • Edgar (US Regulatory) • 05/22/2026 09:20:13 PM
- NervGen Announces Pricing of US$60.0 Million Public Offering of Securities • GlobeNewswire Inc. • 05/22/2026 03:27:00 AM
- Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] • Edgar (US Regulatory) • 05/21/2026 08:34:51 PM
- NervGen Announces Proposed Public Offering of Securities • GlobeNewswire Inc. • 05/21/2026 08:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/18/2026 08:19:44 PM
- NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 05/18/2026 11:15:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/15/2026 08:28:48 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/07/2026 08:06:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/27/2026 09:05:57 PM
- NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer • GlobeNewswire Inc. • 04/27/2026 11:30:00 AM
- NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference • GlobeNewswire Inc. • 04/13/2026 11:45:00 AM
- NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 03/31/2026 11:45:00 AM
- Form 40-F - Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)] • Edgar (US Regulatory) • 03/31/2026 11:30:34 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/13/2026 09:04:36 PM
- NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange • GlobeNewswire Inc. • 03/12/2026 08:15:00 PM
- NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs • GlobeNewswire Inc. • 03/04/2026 12:30:00 PM
- NervGen Pharma to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/18/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/13/2026 09:05:54 PM
- NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams • GlobeNewswire Inc. • 02/12/2026 09:15:00 PM
- NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium • GlobeNewswire Inc. • 02/11/2026 12:00:00 PM
- NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury • GlobeNewswire Inc. • 02/09/2026 12:00:00 PM
- NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing • GlobeNewswire Inc. • 01/20/2026 12:00:00 PM
- NervGen Pharma Begins Trading on Nasdaq Today • GlobeNewswire Inc. • 01/08/2026 11:30:00 AM
